St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
The CTP facilitates and centralizes high-quality, competitively funded peer-reviewed pharmacokinetic (PK) & pharmacodynamic (PD) research in both a clinical and preclinical setting at St. Jude.
The CTP facilitates high-quality, competitively funded, peer-reviewed pharmacokinetic/pharmacodynamic translational research. Its key functions include:
The CTP resources have been and will continue to expand research horizons and funding by providing outstanding expertise in conducting pharmacokinetic and pharmacodynamic studies, developing novel biomedical models, and providing the highest quality of data while performing these studies in a cost-effective manner.
As the PI of complex clinical trials, such as SJDAWN and SJMB12, I recognize the importance pharmacokinetic studies play in determining if the medicine is getting to our patient’s cancer in appropriate concentrations. Having the CTP, here at St Jude, means that not only do we get incredible in-house expertise to measure drug concentrations in our patients but that we also get state-of-the art sample receipt, processing, storage, and distribution whenever needed. This is an essential resource to support our trials and, most importantly, to help improve therapy.
Dr. Giles Robinson, Associate Member
Major instrumentation includes:
The CTP has access to other Pharmaceutical Sciences division equipment, including:
Modeling and simulation activities use both computer workstations and the St. Jude supercomputing cloud. Pharmacometric software includes:
Members access the CTP’s clinical and preclinical services by requesting a consultation through the SRM2 portal. All clinical protocols will go through the CTP for Functions 1 and 2 (protocol implementation and sample acquisition) if they include PK/PD studies and access to analytical assay services (Functions 3 and 4). Preclinical bioanalysis is exempted from Function 3 and is performed on a fit-for-purpose basis, typically, a non-validated but rigorously qualified assay. Study design/biomedical modeling (Function 5) is via discussion between investigators and CTP.
View Details
Markos Leggas, PhD
Member, St. Jude Faculty
Director, Center for Translational Pharmacology
Markos Leggas, PhD
Member, St. Jude Faculty
Director, Center for Translational Pharmacology
Affiliations
Research Interests
Contact Information
Markos Leggas, PhD
Pharmacy and Pharmaceutical Sciences
MS 313, Room I5104
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 381053678
View Details
Kristine Crews, PharmD, BCPS
Director, Scientific Research
Associate Director, Center for Translational Pharmacology
Clinical Pharmacogenomics Residency Director
Kristine Crews, PharmD, BCPS
Director, Scientific Research
Associate Director, Center for Translational Pharmacology
Clinical Pharmacogenomics Residency Director
Affiliations
Research Interests
Contact Information
Kristine Crews, PharmD, BCPS
Center for Translational Pharmacology
MS 313
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
View Details
Burgess Freeman, PharmD
Associate Director, Center for Translational Pharmacology
Burgess Freeman, PharmD
Associate Director, Center for Translational Pharmacology
Affiliations
Contact Information
Burgess Freeman, PharmD
Center for Translational Pharmacology